Jim Cramer Believes Beam Therapeutics Is a “Speculative Situation”

Beam Therapeutics Inc. (NASDAQ:BEAM) was among the stocks on Jim Cramer’s Mad Money radar as he discussed the recent sell-off in AI-related stocks. A caller asked if the stock is a buy, hold, or “forget about it,” and Cramer replied:

Oh, okay. I’ll tell you, Beam is a speculative situation. They do have some formulations. We don’t want to buy any of these stocks that are heavily shorted because they’re all, by nature, heavily shorted because they don’t have any earnings. I would buy this if you thought that they’ve got something that can save a lot of lives. That’s it. Otherwise, move on.

Beam Therapeutics Inc. (NASDAQ:BEAM) develops precision genetic medicines using base-editing technology to treat serious diseases such as sickle cell disease and liver disorders. On October 7, 2025, an Investing Club member inquired about the stock, and Cramer rejoined:

Man, you are really, that’s the speculative bottom there. I’m sorry. I would like to be more positive about that, but that one, I can’t go with. I’m sorry.

It is worth noting that since the above comment was aired, Beam Therapeutics Inc. (NASDAQ:BEAM) stock has gone up more than 21% as of April 28.

While we acknowledge the risk and potential of BEAM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BEAM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.